A sensitive, specific, and rapid high-performance liquid chromatography (HPLC) method for the determination of ambrisentan enantiomers has been developed and validated. Six chiral columns were tested in a reversed-phase system. Excellent enantioseparation with the resolution more than 2.5 was achieved on Chiralcel OZ-3R (cellulose 3-chloro-4-methylphenylcarbamate) using mixture of 20 mM sodium formate (pH 3.0) with acetonitrile (55:45; v/v). Validation of the HPLC method including linearity, limit of detection, limit of quantification, precision, accuracy, and selectivity was performed according to the International Conference on Harmonisation (ICH) guidelines. The method has an advantage of a very quick chromatographic separation (less than 6 min) and therefore is highly suitable for routine determination of (R)-ambrisentan in enantiopure active pharmaceutical ingredient (S)-ambrisentan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jssc.201101062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of respiratory, thoracic, and mediastinal disorders associated with endothelin receptor antagonists and prostacyclin-related drugs in pulmonary hypertension: a disproportionality analysis based on FAERS.
Expert Opin Drug Saf
December 2024
Department of Rheumatology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing, China.
Background: Adverse drug events (ADEs) for endothelin receptor antagonists (ERAs) and prostacyclin-related drugs (PRDs) have been reported in clinical trials, but large-scale, real-world evaluations for respiratory, thoracic, and mediastinal disorders (RTMD) remain scarce.
Methods: A pharmacovigilance analysis of the FAERS database (Q1 2004~Q2 2024) used the reporting odds ratio (ROR) method for disproportionality analysis to assess the adverse drug events (ADEs) of ERAs and PRDs in pulmonary arterial hypertension, focusing on risks related to RTMD.
Results: Reports of ADEs for ERAs (bosentan, ambrisentan, and macitentan) were 15,286, 36795, and 17,497, respectively, and for PRDs (epoprostenol, treprostinil, iloprost, and selexipag) were 5,477, 57265, 3,247, and 5,504.
Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS).
Expert Opin Drug Saf
October 2024
The First Clinical Medical School, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Article Synopsis
- Letairis (ambrisentan) is an important medication for pulmonary arterial hypertension (PAH), but its safety is being closely examined due to potential adverse effects.
- The study utilized data from the FDA Adverse Event Reporting System from 2007 to 2023, analyzing over 16 million reports of adverse events linked to Letairis, predominantly affecting older female patients.
- Results revealed significant concerns regarding serious outcomes, such as hospitalizations and deaths, particularly related to infections and heart disorders, highlighting the need for careful monitoring of this medication in clinical settings.
New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review.
Cureus
August 2024
Research, Ventolini's Lab, Texas Tech University Health Sciences Center, Odessa, USA.
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a severe lung disease marked by elevated pulmonary arterial pressure, causing symptoms that often lead to late diagnosis and a poor prognosis, with a median life expectancy of only three years.
- The condition involves a combination of factors leading to blockage and stiffening of blood vessels in the lungs, resulting in right heart strain and potential failure.
- A systematic review of recent studies evaluated various PAH treatments, highlighting that while many drugs show promise, most do not offer a cure and some, like imatinib, have undesirable side effects.
Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
JAMA Netw Open
July 2024
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: Endothelin receptor antagonists are first-line therapy for pulmonary arterial hypertension (PAH). The first 2 agents approved in the class, bosentan and ambrisentan, initially carried boxed warnings for hepatotoxicity and required monthly liver function tests (LFTs) as part of a risk evaluation and mitigation strategy (REMS); however, in 2011, as further safety data emerged on ambrisentan, the boxed hepatotoxicity warning and LFT requirements were removed.
Objective: To analyze changes in the use of and LFT monitoring for ambrisentan and bosentan after changes to the ambrisentan labeling and REMS.
Prescription patterns of ambrisentan in some cities of Colombia.
Clin Respir J
March 2024
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma S. A, Pereira, Risaralda, Colombia.
Introduction: Ambrisentan is a selective type A endothelin receptor antagonist that has shown significant effectiveness and safety in the management of patients with pulmonary hypertension. Its use pattern with real-world evidence in Colombia is unknown.
Objective: The objective of this study is to determine the prescription patterns of ambrisentan in some cities of Colombia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!